Armata Pharmaceuticals Receives $3.7 Million in Additional Funding from U.S. Department of War

Filing content

Armata Pharmaceuticals announced that it has received an additional $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development program for AP-SA02.